M&A / Deals Kailera makes history with record-breaking $625m IPO Pharmaceutical TechnologyKailera's IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Kailera’s IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials. M&A / DealsRead full story Post navigation Previous: Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery toolNext: Trump signs order to hasten psychedelic medicine access Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
